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Abstract
Purpose
To determine the frequency and prognostic value of elevated microsatellite alterations at se-
lected tetranucleotide repeats (EMAST) in metastatic colorectal cancer (mCRC) patients in
relation to microsatellite instability (MSI) status and MSH3 protein expression.
Material and Methods
The frequency of EMAST was evaluated in mCRC patients with MSI tumors and microsatel-
lite stable (MSS) tumors. A literature overview was performed to compare the frequency of
EMAST in our study with existing data. Immunohistochemistry for MSH3 was compared
with EMAST status. Outcome was studied in terms of overall survival (OS) of mCRC pa-
tients with MSI and MSS tumors.
Results
EMAST was evaluated in 89 patients with MSI tumors (including 39 patients with Lynch syn-
drome) and 94 patients with MSS tumors. EMAST was observed in 45.9% (84 out of 183) of
patients, with an increased frequency in MSI tumors (79.8% versus 13.8%, p < 0.001). We
found no correlation between EMAST and MSH3 protein expression. There was no effect of
EMAST on prognosis in patients with MSS tumors, but patients with MSI / non-EMAST tu-
mors had a significantly better prognosis than patients with MSI / EMAST tumors (OS: HR
3.22, 95% CI 1.25-8.30).
Conclusion
Frequency of EMAST was increased in mCRC patients with MSI tumors, compared to MSS
tumors. Our data suggest that the presence of EMAST correlates with worse OS in these
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patients. There was no effect of EMAST on the prognosis of patients with MSS tumors. A
limitation of our study is the small number of patients in our subgroup analysis.
Introduction
Colorectal cancer (CRC) carcinogenesis is a multistep process in which different pathways are
involved, among which microsatellite instability (MSI) is important [1–3]. MSI is characterized
by a deficient mismatch repair system, which leads to cancer development through the accu-
mulation of unrepaired frame shift mutations in simple repeat sequences or microsatellites [4].
To date several mismatch repair (MMR) proteins have been identified in humans: MSH2,
MSH3, MSH6, MLH1 and PMS2. MSH2 forms a heterodimer with MSH6 or MSH3, giving
rise to MutSα or MutSβ, respectively [5]. MutSα recognizes single base-pair mismatches and
small insertion-deletion loops (IDLs), whereas MutSβ preferentially recognizes larger mis-
matches and IDLs. Furthermore, MLH1 and PMS2 formMutLα, which acts as a molecular
matchmaker. In addition to the primary MMR defect, secondary loss of MMR proteins can
occur as a consequence ofMSH3 andMSH6 frame shift mutations promoted byMLH1 inacti-
vation [6,7] or because of MSH3 and MSH6 protein degradation in tumors not expressing
their heterodimeric partner MSH2 [8,9]. As a result, single or combined defects of MMR sub-
units (MutSα, MutSβ and MutL) can variably underlie the genetic instability of MSI tumors.
Germline alterations of MMR genes are the cause of MSI in Lynch syndrome patients [10].
MSI is also observed in 10–20% of patients with sporadic CRC, usually due to promoter hyper-
methylation of theMLH1 gene [11,12]. MSI tumors have distinctive features, such as location
in the proximal colon, a high incidence of lymphocytic infiltrate, a poorly differentiated, mu-
cinous or signet ring histology [13]. MSI tumors are associated with a favorable prognosis in
early stage colon cancer [14].
A distinct form of MSI is observed in several types of cancers and is called ‘elevated micro-
satellite alterations at selected tetranucleotide repeats’ (EMAST) in contrast to mono-, and di-
nucleotide based instability in common MSI [15–20]. Only a few studies describe this subtype
in a small number of CRC patients [21–24]. EMAST has not been linked to major defects in
DNAmismatch repair. Heterogeneous and reduced protein expression of MSH3 was observed
in association with EMAST in CRC [21–24]. More recent reports suggest that MSH3 deficiency
is the cause of EMAST in human CRC cells [25,26]. The link between MSH3 and EMAST sug-
gests an acquired effect, as no germ line mutation inMSH3 has ever been demonstrated [4].
There is a broad range in the prevalence of EMAST is CRC and the biological significance of
EMAST in CRC is not clear. Only one article described an association with outcome for stage
II/III CRC patients.[27]
Only limited data is available regarding EMAST or MSH3 expression in CRC patients. In
the current study we evaluated the frequency of EMAST in MSI and microsatellite stable
(MSS) CRC tumors. In addition, we assessed in an exploratory analysis the role of EMAST as a
prognostic biomarker in metastatic CRC (mCRC) patients.
Material and Methods
Patient populations
Data were derived from mCRC patients included in two large phase III studies: CAIRO (Clini-
calTrials.gov NCT00312000) (n = 820) and CAIRO2 (n = 755) (ClinicalTrials.gov
NCT00208546), of which the results have been published previously [28,29]. Collection of
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formalin-fixed paraffin-embedded (FFPE) material of the primary tumor was part of the initial
protocol in both studies. To determine the frequency and prognostic value of EMAST in
mCRC patients with MSI tumors we selected 50 mCRC patients with MSI tumors treated in
both CAIRO studies. Since MSI is relatively rare in mCRC we combined the patients of the
CAIRO (n = 19) and the CAIRO2 (n = 31) study. No validation cohort could be selected for
MSI patients. To further evaluate the relation between EMAST and MSI, we retrieved 39 tu-
mors from CRC patients (anonymous samples) with known Lynch syndrome (stage I-IV)
from our own database (that has been set up conform the guidelines of the local medical ethical
committee (Commissie Mensgebonden Onderzoek Radboudumc) with written informed con-
sent of the patients, from which use of tissue is approved for this study). To determine the fre-
quency and prognostic value of EMAST in mCRC patients with MSS tumors we selected 54
patients of the CAIRO study with comparable characteristics (test group). Patients within the
test group were all treated with first-line capecitabine monotherapy for at least 3 cycles, locali-
zation of the primary tumor in colon or recto- sigmoid which was resected, WHO performance
score 0, normal baseline serum lactate dehydrogenase (LDH) concentration, and had not re-
ceived prior adjuvant chemotherapy. In addition, we randomly selected 40 additional mCRC
patients with MSS tumors treated in the same CAIRO study as a validation group. (Fig 1)
Fig 1. Flowchart of selected CRC patients to determine the frequency and prognostic value of
EMAST.
doi:10.1371/journal.pone.0124538.g001
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EMAST analysis
Genomic DNA was extracted from four to eight manually microdissected 30 μm section of
FFPE tissue of the primary tumors. Areas containing>50% tumor cells were selected by micro-
scopic evaluation on a reference slide stained with H&E. Genomic DNA from microdissected
tissues was isolated using the QIAamp DNAmicro kit (Qiagen, Valencia, CA) following the
manufacturer’s instructions. DNA concentration was determined at 260 nm using the Nano-
drop ND-1000 spectrophotometer (Nanodrop Technologies, Inc., Wilmington, DE, USA).
EMAST analysis was performed in duplicate on normal and tumor DNA of the selected pa-
tients. EMAST status was determined by PCR and GeneScan analysis using five tetranucleotide
markers: MYCL1, D8S321, D9S242, D20S82 and D20S85 (S1 Table) [23]. A tumor was defined
EMAST if at least two of the five markers showed instability and non-EMAST if only one or
none of the markers showed instability [22].
Patients were analyzed for the frequency and prognostic value in four different groups: pa-
tients with combined MSI and EMAST tumors (MSI / EMAST), patients with combined MSI
and non-EMAST tumors (MSI / non-EMAST), patients with combined MSS and EMAST tu-
mors (MSS / EMAST) and patients with combined MSS and non-EMAST tumors (MSS / non-
EMAST). The frequency of EMAST was compared for patients with MSI and MSS tumors.
The outcome was analyzed within the group of patients with MSI tumors (excluding the Lynch
syndrome patients) for EMAST compared to non-EMAST tumors and within the group of pa-
tients with MSS tumors for EMAST compared to non-EMAST tumors.
Immunohistochemistry MSH3
Immunohistochemistry (IHC) was performed on tissue microarrays (TMA) of the primary tu-
mors of 549 eligible randomized patients in the CAIRO study as previously described.[30]
4 μm slides were cut of every TMA and mounted on glass. Xylene and ethanol were used for
deparaffinization and dehydration of the TMA slides. Water and phosphate-buffered saline
(PBS) were used for washing of the slides. Endogenous peroxidase activity was blocked with
3% hydrogen peroxide in PBS for 30 min and slides were washed with water, after which heat-
induced epitope retrieval was performed. The slides were stained with a monoclonal antibody
against MSH3 (clone ERP4334; Epitomics—an Abcam company, Burlingame, CA, USA), dilu-
tion 1:5000. Two independent investigators performed the scoring, and if the slide scoring was
not unambiguous, the opinion of a third investigator (pathologist IDN) was final. Staining pat-
tern of the MSH3 protein was evaluated by using the normal epithelial, stromal and inflamma-
tory cells as internal control. Low MSH3 protein expression was defined as<85% brown
staining of cell cores in tumor cells and high MSH3 protein expression was defined as85%
brown staining of cell cores in tumor cells and not applicable if neither tumor nor stromal cells
showed MSH3 protein expression [21].
MSI, hypermethylation of the MLH1 gene promoter and BRAF status
For samples of both CAIRO studies, immunohistochemistry (IHC) was performed on FFPE
tissue with antibodies against MLH1, MSH2, MSH6 and PMS2. In addition, MSI analysis was
performed where there was an absence of MMR protein expression or equivocal IHC results.
MSI status was determined using two microsatellite markers (BAT 25 and BAT 26). If only one
of these markers showed instability, the analysis was extended with four additional markers
(BAT 40, D2S123, D5S346, and D17S250). A tumor was defined as MSI if at least two of the six
markers showed instability or MSS if none of the markers showed instability. Tumors with
only one of the markers showing instability were defined as MSI-low and included in the MSS
EMAST in Metastatic Colorectal Cancer Patients
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category.[30] Hypermethylation status of theMLH1 gene promoter and the BRAF V600E mu-
tation status, was assessed as described previously [30–32].
Statistical analysis
For the EMAST analysis, patients were divided into two categories: EMAST and non-EMAST
tumors. The association between EMAST and MSH3 protein expression was investigated with
a logistic regression model with independent factors group and MSH3 expression. OS was de-
fined as the time from the date of randomization to the date of death from any cause. OS curves
were estimated using the Kaplan—Meier method and compared using a Cox proportional haz-
ard model. All tests were two-sided and p<0.05 was considered as statistically significant. All
analyses were conducted using the SAS system version 9.2.
Literature search strategy, inclusion criteria, and data extraction
We reviewed the literature on the frequency of EMAST in CRC patients with MSI and MSS tu-
mors. A search was conducted of Medline, PubMed, and the Cochrane Library from January
1990 to April 2014 with an English-language restriction, using the following search terms:
EMAST, tetranucleotide repeat, in combination with colon cancer and colorectal cancer. Origi-
nal publications were selected if the abstract contained data for patients with EMAST. In case
of duplicate publications, the most recent and/or most complete study was included. Publica-
tions were excluded if frequency of EMAST was limited to either patients with MSI or
MSS tumors.
Results
Prevalence of EMAST
Overall, EMAST was observed among 45.9% of a total of 183 tumors (Table 1). Frequency of
EMAST was significantly higher among patients with MSI tumors compared to MSS tumors:
79.8% compared to 13.8% (p<0.001).
In patients with MSS / EMAST tumors instability was generally shown at 2 EMAST loci
(69.2%, 9 out of 13), whereas in patients with MSI / EMAST tumors instability was frequently
shown at 4 (33.8%, 24 out of 71), or 5 (50.7%, 36 out of 71) EMAST loci (Fig 2A). The highest
Table 1. Prevalence of EMAST and non-EMAST tumors in the different patient groups.
EMAST non-EMAST Total number of patients p value
Patients with MSI tumors
mCRC 84.0% 16.0% 50
Lynch syndrome 74.4% 25.6% 39 0.113
Total 79.8% 20.2% 89
Patients with MSS tumors
Test group of patients 11.1% 88.9% 54
Validation group of patients 17.5% 82.5% 40 0.160
Total 13.8% 86.2% 94
All patients Total 45.9% 54.1% 183
p value represent heterogeneity between groups
Abbreviations: EMAST = elevated microsatellite alterations at selected tetranucleotide repeats, MSI = microsatellite instability,
MSS = microsatellite stability
doi:10.1371/journal.pone.0124538.t001
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frequency of instability in EMAST tumors was demonstrated at the D20S82 locus (91.7%, 77
out of 84), followed by the MYCL1 locus (86.9%, 73 out of 84), the D9S242 locus (84.5%, 71
out of 84), the D8S321 locus (72.6%, 61 out of 84) and the D20S85 locus (65.5%, 55 out of 84)
(Fig 2B).
EMAST and MSH3
The majority of mCRC patients (n = 381, 69.4%) had a high expression of MSH3 in tumor cells
(Fig 3). 21.1% of tumors demonstrated nuclear heterogeneity by expression of both positive
and negative nuclei upon MSH3 IHC staining (Fig 3A–3C). Both MSH3 expression and
EMAST status was known in 139 patients. Heterogeneous or high MSH3 protein expression
was not correlated to EMAST status (p = 0.088 and p = 0.856, respectively).
Outcome of patients with MSI tumors
Patients with MSI / EMAST tumors were mostly female (52% versus 22%, respectively,
p = 0.038) (Table 2). Moreover, EMAST tumors were more frequently located above the recto-
sigmoid area (93% versus 63%, p = 0.006).
Fig 2. Frequency of instable EMASTmarkers (A) and frequency of affected EMAST loci (B),
subdivided by patients with MSI and MSS tumors.
doi:10.1371/journal.pone.0124538.g002
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Median OS was significantly worse for patients with MSI / EMAST compared to MSI / non-
EMAST tumors treated in both CAIRO studies (11.4 versus 39.4 months, respectively, HR
3.22, 95% CI 1.25–8.30) (Table 3).
MSI / EMAST and the relation to MMR proteins
The distribution of loss of MMR proteins in mCRC tumors is summarized in Fig 4A. Most pa-
tients with MSI tumors showed loss of MLH1 and/or PMS2 protein expression (72.0%, 36 out
of 50 patients). Loss of MSH2 and/or MSH6 protein expression was found in 18.0% (9 out of
50) of patients. These patients are likely Lynch or Lynch-like syndrome patients. Only 7.1% (3
out of 42) of patients with a MSI / EMAST tumor showed loss of expression of the MSH6 pro-
tein, compared to 62.5% (5 out of 8) of patients with MSI / non-EMAST tumors.
Hypermethylation of theMLH1 gene promoter (32 out of 40 patients) and BRAFmutations
(24 out of 40 patients) were limited to the patients with a MSI / EMAST tumor (p< 0.001 and
p = 0.004 respectively).
EMAST in patients with Lynch syndrome
In order to further analyze the relation of MSI and EMAST we selected 39 patients with known
Lynch syndrome (with germ line mutations inMSH2 gene (n = 11),MLH1 gene (n = 10),
MSH6 gene (n = 10) and PMS2 gene (n = 8)). The majority of this population showed EMAST
(29 out of 39 patients). None of the patients showed hypermethylation of theMLH1 gene pro-
moter, and all tumors were BRAF wild-type. Nine out of 10 patients presenting with non-
EMAST tumors had a germline mutation inMSH6 (Fig 4B).
Outcome of patients with MSS tumors
Baseline patient and tumor characteristics for patients with MSS tumors (test group and valida-
tion group), subdivided by EMAST and non-EMAST tumors are presented in Table 2. There
Fig 3. Staining pattern of MSH3 protein expression.Heterogeneous MSH3 protein expression (A),
demonstrated by expression of both brown (positive) and blue (negative) nuclei upon MSH3 IHC staining.
LowMSH3 protein expression was defined as <85% brown staining of cell cores in tumor cells (B) and high
MSH3 protein expression was defined as85% brown staining of cell cores in tumor cells (C).
doi:10.1371/journal.pone.0124538.g003
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was no significant difference in outcome for patients with EMAST compared to patients with
non-EMAST tumors (Table 3).
Review of the literature
The literature search identified 7 studies in which EMAST was described in stage I-IV CRC pa-
tients with MSI and MSS tumors [21–24,27,33,34]. Two studies were excluded: one study de-
scribed the same population [23] and one study assessed the prevalence of EMAST solely in
Table 2. Baseline patient and tumor characteristics of patients with MSI and MSS tumors, subdivide by EMAST and non-EMAST tumors.
Patients with MSI tumors Patients with MSS tumors
Test group Validation group
EMAST non-
EMAST
EMAST non-
EMAST
EMAST non-
EMAST
n = 42 n = 8 p value n = 6 n = 48 p value n = 7 n = 33 p value
Median age (range) 68 (34–
84)
59 (37–73) 0.131 72 (47–
77)
66 (34–79) 0.749 71 (58–
76)
67 (39–81) 0.161
Sex
male 20 (48%) 7 (88%) 0.038 5 (83%) 31 (65%) 0.651 5 (71%) 22 (67%) 0.338
female 22 (52%) 1 (22%) 1 (17%) 17 (35%) 2 (29%) 11 (33%)
WHO performance status
PS0 26 (62%) 4 (50%) 0.156 6 (100%) 48 (100%) - 3 (42%) 22 (67%) 0.045
PS1 14 (33%) 4 (50%) - - 3 (42%) 11 (33%)
PS2 2 (5%) - - - 1 (16%) -
Serum LDH
normal 32 (76%) 4 (50%) 0.110 6 (100%) 48 (100%) - 5 (71%) 23 (70%) 0.348
abnormal 10 (24%) 4 (50%) - - 2 (29%) 10 (30%)
Previous adjuvant therapy
yes 5 (12%) 2 (25%) 0.239 - - - 3 (42%) 5 (15%) 0.108
no 37 (88%) 6 (75%) 6 (100%) 48 (100%) 4 (58%) 28 (85%)
Localization of the primary tumor
colon 93 (93%) 5 (63%) 0.006 5 (83%) 42 (88%) 0.416 3 (42%) 20 (61%) 0.869
recto sigmoid - 2 (25%) 1 (17%) 6 (12%) - 1 (3%)
rectum 2 (5%) 1 (12%) - - 4 (58%) 11 (33%)
multiple tumor - - - 1 (3%)
unknown 1 (2%) -
Histology of the primary tumor
adenocarcinoma 22 (52%) 5 (63%) 0.144 5 (83%) 35 (73%) 0.183 7 (100%) 24 (73%) 0.141
mucinous adenocarcinoma (>50%
WHO)
16 (38%) 2 (25%) 1 (17%) 4 (8%) - 4 (12%)
adenocarcinoma + mucinous
component
4 (10%) - - 6 (13%) - 4 (12%)
other - 1 (12%) - 3 (6%) - 1 (3%)
BRAF mutation status
mutation 24 (57%) - 0.004 - 5 (11%) 0.590 - - 0.677
wild-type 16 (38%) 7 (88%) 6 (100%) 40 (83%) 7 (100%) 31 (94%)
unknown 2 (5%) 1 (12%) - 3 (6%) - 2 (6%)
NOTE: Statistically signiﬁcant results are set in bold
Abbreviations: MSI = microsatellite instability, MSS = microsatellite stability, EMAST = elevated microsatellite instability at selected tetranucleotide repeats
doi:10.1371/journal.pone.0124538.t002
EMAST in Metastatic Colorectal Cancer Patients
PLOS ONE | DOI:10.1371/journal.pone.0124538 April 17, 2015 8 / 13
Table 3. Overall survival of patients with MSI and MSS tumors, subdivided by EMAST and non-EMAST tumors.
EMAST non-EMAST HR
(months (95% CI)) (months (95% CI)) (95% CI) p value
MSI tumors n = 42 n = 8
11.4 (7.3–15.6) 39.4 (8.0-NE) 3.22 (1.25–8.30) 0.010
Test group (MSS tumors) n = 6 n = 48
22.4 (22.4-NE) 19.1 (14.4–23.7) 0.33 (0.10–1.07) 0.053
Validation group (MSS tumors) n = 7 n = 33
19.3 (8.4–38.6) 18.2 (14.6–21.9) 1.14 (0.50–2.61) 0.759
NOTE: Statistically signiﬁcant results are set in bold
Abbreviations: EMAST = elevated microsatellite instability at selected tetranucleotide repeats, MSI = microsatellite instability, MSS = microsatellite
stability, CI = conﬁdence interval, HR = hazard ratio, NE = not estimable
doi:10.1371/journal.pone.0124538.t003
Fig 4. Percentage of mCRC patients with MSI tumors and loss of MLH1 and/or PMS2 (MLH1 / PMS2)
andMSH2 and/or MSH6, (MSH2 and MSH6) subdivided in patients with MSI / EMAST tumors and
patients with MSI / non-EMAST tumors. (A). Percentage of patients with known Lynch syndrome and germ
line mutation of the different MSI genes, subdivided in patients with MSI / EMAST tumors and patients with
MSI / non-EMAST tumors (B).
doi:10.1371/journal.pone.0124538.g004
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patients with MSS tumors [27]. Three studies had limited numbers of MSI tumors. Fig 5 sum-
marizes a forest plot of the 5 published studies and the current study on the prevalence of
EMAST in stage I-IV CRC patients with MSI and MSS tumors. EMAST is significantly more
frequent in tumors with MSI (148/174) (RR 4.80, 95% confidence interval 3.90–5.91). Signifi-
cant heterogeneity was observed.
Discussion
This study presents the analysis on the frequency and prognostic value of EMAST in mCRC
patients. Although EMAST was observed in 45.9% of all mCRC patients, it was most pro-
nounced in MSI tumors (79.8%). The frequency of EMAST among MSS tumors (13.8%) was
much lower in our study compared to most studies in stage I-IV CRC [21–24,27,34]. The
broad range of frequency (0.54–60.2%) of EMAST among MSS tumors described in literature
[21–24,27,33,34] might be due the fact that there is no consensus on the definition of EMAST
and the panel required for its diagnosis. Because of the polymorphic nature of tetranucleotide
repeats in the current study we used stringent criteria for the definition of EMAST: at least two
of the five tetranucleotide markers should show instability.
Despite the fact that several small studies (n = 3 to n = 56) [21–24,33,34] demonstrated that
MSI invariably is associated with EMAST, the correlation between EMAST and MSI is not
widely accepted. We found a high frequency of EMAST in MSI tumors, which was confirmed
in a analysis of the existing literature in stage I-IV CRC (Fig 5). Only a small subset of patients
with MSI tumors is non-EMAST. Interestingly, the majority of patients with MSI / non-
EMAST tumors showed loss of MSH6. This is in line with the fact that MSH6 is only involved
in mononucleotide mismatch repair [35,36]. Patients with MSI / non-EMAST tumors are
more often male and tumors developed more frequently in the rectum, these characteristics are
comparable to patients withMSH6 germline mutations [37]. In our population of MSI tumors
the presence of EMAST is correlated withMLH1 deficiency, which causes a total DNAmis-
match repair defect, both in Lynch syndrome as well as in the sporadic setting, confirming ear-
lier observations [21,27].
Data about the EMAST phenotype in CRC are scarce and underlying mechanism(s) remain
unclear. The earliest reports suggested that EMAST might be associated with mutations in the
TP53 gene [16,17] or that environmental carcinogens may exacerbate this phenotype [38] in
cancers other than CRC. Later on, an association was made between loss of MSH3 and EMAST
in CRC [21]. Due to the fact that MutSβ has a strong affinity for recognizing more than two un-
paired nucleotides and genetic complementation of MSH3 deficiency in human cells increased
stability at loci containing dinucleotide and tetranucleotide repeats [39], it was argued that that
loss of MutSβ due to MSH3 inactivation may result in MSI not only at loci containing dinucle-
otide repeats, but also at loci with tetranucleotide repeats, such as EMAST [21]. Recent studies
Fig 5. Forest plot for the association of prevalence of EMAST in patients with MSI compared to MSS
tumors in stage I-IV CRC.
doi:10.1371/journal.pone.0124538.g005
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confirm the association between loss of MSH3 and EMAST in CRC, however the exact under-
lying mechanism remains unknown [25,26]. We failed to demonstrate a correlation between
MSH3 protein expression and EMAST. Actually, we did find the heterogeneous expression pat-
tern of MSH3 in 21.1% of patients as described by others, although this was not correlated to
EMAST. However our study had a small number of patients. Another possible explanation for
the difference between our study and previous studies might be a potential undersampeling
bias since we used one TMA specimen per tumor instead of full tumor slides.
We demonstrate that patients with MSI / non-EMAST tumors had a significantly better
prognosis compared to patients with MSI / EMAST tumors. The addition of EMAST to MSI
tumors seems to worsen overall prognosis and survival. The MSI / non-EMAST group would
be expected to be enriched forMSH6 deficiency since EMAST would be identified with a total
DNAmismatch repair defect, such as withMLH1 orMSH2 deficiency. Our results on the cor-
relation of EMAST with clinical outcome should be interpreted with caution due to the small
number of patients in the different subgroups.
In summary, the frequency of EMAST among mCRC patients with MSS tumors is low
compared to patients with MSI tumors. There was no correlation between EMAST and
MSH3 protein expression. We did find a clear link between MSI and EMAST, and outcome
was significantly better for mCRC patients with MSI / non-EMAST tumors. Further studies
are warranted to elucidate the molecular basis for EMAST and to show whether the tetranu-
cleotide alterations observed in EMAST tumors may have a functional impact by themselves
or just represent bystander alterations in a subset of tumors with specific defects in DNA rep-
lication and repair.
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